The European Medicines Agency issued a negative "trend" vote for Biotech Inc.'s (Nasdaq: XBIT) marketing authorization application for its candidate antibody for the treatment of colorectal cancer. The stock price plunged $6.79 to close at $10.23.
Biotech receives negative trend voteApril 21, 2017 at 19:13 PM EDT
The European Medicines Agency issued a negative "trend" vote for Biotech Inc.'s (Nasdaq: XBIT) marketing authorization application for its candidate antibody for the treatment of colorectal cancer. The stock price plunged $6.79 to close at $10.23.
Related Stocks:
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|